Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2024-05-01 00:00:00 ET · period of report 2024-01-02 · accession 0001883850-24-000012 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2024-05-01 | 2024-01-02 | REGN | YANCOPOULOS GEORGE | Pres, CSO, Bd. Co-COB, Dir | S - Sale | $900.00 | -16.8K | 180.0K | -9% | -$15.16M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-02 | S | D | 16,848 | $900.00 | 180,000 | I By Trust for Chldn. | — | — | (F2) As investment trustee of trusts for the benefit of the reporting person's children. |